Molecular Partners logo

Initial Public Offering on Nasdaq

USD 63.8 million
Lead Manager
;

Molecular Partners

Lead Manager

Kempen & Co acted as Lead Manager in Molecular Partners’ USD 63.8m Initial Public Offering on Nasdaq

Transaction highlights

  • Initial Public Offering on the Nasdaq Global Select Market of 3,000,000 ADSs, corresponding to 3,000,000 underlying ordinary shares and generating gross proceeds of USD 63.8m
  • The offer price was set at USD 21.25 per ADS which corresponds to a price of CHF 19.05 per underlying ordinary share and represents a 9.5% discount vis-a-vis the last closing price of Molecular Partners’ shares on the SIX Stock Exchange prior to pricing on 16 June 2021
  • The new shares underlying the ADSs represent 9.3% of Molecular Partners’ entire share capital post offering
  • Molecular Partners will use the transaction proceeds to fund and expand their current clinical pipeline as well as for working capital and other general corporate purposes
  • Kempen & Co has a long-standing relationship  with Molecular Partners, last acting as Joint Bookrunner in the company’s CHF 80.2m capital increase via an Accelerated Bookbuild Offering in July 2020 and, via Kempen & Co’s Trading Desk, executing various block trades over the years, including a major block in Q3 2019
  • In 2021 year to date, Kempen & Co has already executed 15 transactions for European life sciences companies of which 4 US Nasdaq IPOs

Company description

Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Background Kempen & Co Life Sciences & Healthcare

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

  • Joint Bookrunner in the SEK 301m Capital Increase by Q-linea
  • Co-Manager in the USD 176 million Nasdaq Initial Public Offering by Achilles Therapeutics 
  • Joint Bookrunner in the €30 million Capital Increase by GenSight Biologics
  • Lead Manager in the USD 101 million Nasdaq Initial Public Offering by LAVA Therapeutics
  • Joint Bookrunner in the USD 120 million Nasdaq Initial Public Offering by European Biotech Acquisition Corp (EBAC)
  • Joint Bookrunner in the SEK 1.1 billion capital increase by Oncopeptides
  • Joint Global Coordinator and Joint Bookrunner in the SEK 962 million Capital Increase by BioInvent
  • Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
  • Co-Manager in the USD 115 million US Public Offering by Y-mAbs Therapeutics
  • Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
  • Co-Manager in the USD 190 million Nasdaq Initial Public Offering by Pharvaris
  • Bookrunner in the USD 518 million US Public Offering by CureVac
  • Lead Manager in the USD 120 million US Public Offering by Merus 
  • Financial Adviser to DCprime in its merger with Immunicum 
  • Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
  • Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
  • Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
  • Lead Manager in the USD 95.1 million Nasdaq Initial Public Offering by Galecto
  • Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
  • Bookrunner in the USD 245 million Nasdaq Initial Public Offering by CureVac
  • Co-Manager in the USD 49.0 million US Public Offering by Centogene
  • Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
  • Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
  • Co-Manager in the USD 690 million US Public Offering by Ascendis Pharma
  • Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp, thereby becoming a Nasdaq listed company and securing USD 253 million
  • Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
  • Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
  • Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
  • Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
  • Co-Manager in the USD 862 million Global Offering by argenx
  • Joint Bookrunner in the SEK 1.41 billion Capital Increase by Oncopeptides

Contact

Jan De Kerpel
Kathrin Erfurth

Transactions